Related Experiment Videos
Antimicrobial activity of phenothiazines
Leonard Amaral1, Miguel Viveiros, Joseph Molnar
1Unit of Mycobacteriology/UPMM/Instituto de Higiene e Medicina Tropical/Universidade de Lisboa, 1394-008 Lisbon, Portugal. lamaral@ihmt.unl.pt
In Vivo (Athens, Greece)
|January 14, 2005
Summary
Phenothiazines, like thioridazine, show promise in combating drug-resistant infections such as multidrug-resistant tuberculosis and MRSA. These compounds effectively kill intracellular pathogens at clinical concentrations, offering new therapeutic avenues.
Area of Science:
- Pharmacology and Infectious Diseases
- Antimicrobial Resistance Research
- Drug Repurposing
Background:
- Multidrug-resistant Mycobacterium tuberculosis (MDRTB), antibiotic-resistant Plasmodium falciparum, and Methicillin-resistant Staphylococcus aureus (MRSA) pose significant global health threats, causing millions of deaths annually.
- Increasing resistance to established antibiotics, including emerging vancomycin resistance in Staphylococcus aureus, necessitates the exploration of novel therapeutic strategies.
- Existing treatments face challenges due to widespread antimicrobial resistance, driving the search for alternative drug classes.
Purpose of the Study:
- To review the scientific and medical evidence supporting the use of phenothiazines, specifically thioridazine, for managing multidrug-resistant bacterial and parasitic infections.
- To explore the potential of thioridazine as a therapeutic agent against intracellular MDRTB and MRSA.
- To discuss the broader antimicrobial and antiparasitic activities of phenothiazines and their mechanisms of action.
Main Methods:
- Literature review of existing scientific and medical studies on phenothiazines and their antimicrobial properties.
- Analysis of data regarding the efficacy of thioridazine against intracellular MDRTB and MRSA at clinical concentrations.
- Examination of the mechanisms underlying phenothiazine antimicrobial effects, including efflux pump regulation.
Main Results:
- Thioridazine demonstrates efficacy against intracellular multidrug-resistant Mycobacterium tuberculosis (MDRTB) and Methicillin-resistant Staphylococcus aureus (MRSA) at concentrations achievable in clinical settings.
- Phenothiazines exhibit activity against various protozoa and parasites, suggesting a broad spectrum of antipathic potential.
- The compounds show potential in modulating efflux pumps, a key mechanism contributing to multidrug resistance in bacteria.
Conclusions:
- Thioridazine, a phenothiazine derivative, presents a viable option for the management of severe antibiotic-resistant infections, including MDRTB and MRSA.
- The review supports the repurposing of phenothiazines for treating challenging infections caused by antibiotic-resistant pathogens.
- Further investigation into phenothiazines' mechanisms and clinical application is warranted for combating global antimicrobial resistance.